Here's the fulcrum of this story, the paper where the Bluestone group and collaborators turn the mouse anti-human CD3 monoclonal into a chimeric, non-Fc activating molecule: Alegre et al, 1994
#MonoclonalAntibody #MolecularBiology #AntibodyEnginering #DrugDiscovery #DrugDevelopment #NatureMedicine #Diabetes #Type1Diabetes #Immunotherapy